07:00 , Apr 7, 2003 |  BioCentury  |  Finance

1Q Setbacks

1Q Setbacks Company Setback Abgenix (ABGX)/SangStat (SANG) Companies discontinue development of ABX-CBL after it fails to meet the primary endpoint of increased survival compared to Atgam anti-thymocyte globulin in a Phase II/III trial in graft...
08:00 , Mar 10, 2003 |  BC Week In Review  |  Clinical News

Atgam: Marketed to treat of moderate to severe aplastic anemia in patients who are unsuitable for bone marrow transplantation

In a long-term U.S. study in 122 patients, 55% of patients given Atgam plus cyclosporine were alive at 7 years. Data were published in the Journal of the American Medical Association. Pharmacia Corp. (PHA), Peapack,...
08:00 , Feb 24, 2003 |  BC Week In Review  |  Clinical News

ABX-CBL: Phase II/III

The companies discontinued development of ABX-CBL after the compound failed to meet the primary endpoint of increased survival at 180 days compared to Atgam anti-thymocyte globulin. The Phase II/III trial included patients with acute...
08:00 , Feb 24, 2003 |  BioCentury  |  Finance

Ebb & Flow

Investors typically pay a premium for biotech earnings, largely on the promise of future growth. Thus the fact that NPS Pharmaceuticals (NPSP) is getting Enzon on the cheap on a price-to-earnings basis implies that NPSP...
08:00 , Feb 18, 2003 |  BC Extra  |  Clinical News

Abgenix, SangStat end ABX-CBL development

ABGX and SANG said they will end development of ABX-CBL, an anti- CD147 antibody, after the compound failed to increase survival at 180 days compared to Atgam anti-thymocyte globulin in a Phase II/III trial in...
07:00 , Jul 15, 2002 |  BC Extra  |  Clinical News

SangStat completes Phase II/III GvHD enrollment

SANG completed enrollment in an international Phase II/III study comparing ABX-CBL to Atgam anti-thymocyte globulin in treating steroid-resistant graft-versus-host disease (GvHD) in allogeneic bone marrow transplant patients. SANG said there were 92 evaluable patients. The...
08:00 , Jan 11, 1999 |  BioCentury  |  Strategy

SangStat's bid for critical mass

With the approval of Thymoglobulin, the second major piece of its transplant package, and expected approval of its cyclosporine in Europe, SangStat Medical Corp. believes it has the critical mass to attain significant growth and...
07:00 , May 4, 1998 |  BC Week In Review  |  Clinical News

Thymoglobulin rabbit anti-thymocyte globulin: NDA submitted; Phase III data presented

Twelve-month results of a Phase III trial of Thymoglobulin in 162 patients showed survival rates were similar to those with Atgam horse anti-thymocyte globulin, and that less recurrent rejection followed after use of the...
07:00 , May 4, 1998 |  BC Week In Review  |  Clinical News

Thymoglobulin rabbit anti-thymocyte globulin: Phase II

Results of a study of Thymoglobulin in inducing immunosuppression in 72 consecutive patients receiving kidneys showed less severe and less frequent rejection as compared to treatment with Atgam (p=0.014). Lymphopenia was more prolonged with...
08:00 , Jan 19, 1998 |  BC Week In Review  |  Clinical News

Thymoglobulin anti-thymocyte globulin from rabbits data

A Phase II trial of Thymoglobulin in 72 patients showed significant improvement in acceptance of kidney transplants compared to Atgam horse immunoglobulin. Thymoglobulin reduced rejection episodes by 83 percent. Biopsy-proven rejection was 4.2 percent...